ASCO 2018 | bb2121: a promising outlook for the future of multiple myeloma

Howard Burris

The CRB-401 trial (NCT02658929) aims to investigate the efficacy of bb2121 for multiple myeloma (MM) patients. In this interview, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, outlines the preliminary results of the trial and speaks about the possible advances that could be made as a result.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter